Parnell Pharmaceuticals Holdings Ltd. (PARNF)

[Wildbilly]

Parnell Pharmaceuticals Holdings Upgraded to “Hold” by Zacks (PARN)

Posted by Stephan Byrd on Oct 14th, 2015

Parnell Pharmaceuticals Holdings logoParnell Pharmaceuticals Holdings (NASDAQ:PARN) was upgraded by Zacks from a “sell” rating to a “hold” rating in a research report issued on Wednesday, Marketbeat reports.

According to Zacks, “Parnell Pharmaceuticals Holdings Ltd. is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing animal health solutions. It manufactures and markets cattle reproduction, cattle mastitis, anesthetics, laminitis treatment, and orthopedic treatment products. The Company operates in four segments: Companion Animal, Production Animal-Unites States, and Production Animal-rest of the world and Manufacturing Operations. ZYDAX (R), GLYDE (R) and TERGIVE (R) are Parnell’s premium osteoarthritis product suite. Parnell Pharmaceuticals Holdings Ltd. is headquartered in Alexandria, Australia. “

Separately, Piper Jaffray restated a “buy” rating and issued a $12.00 target price (down previously from $16.00) on shares of Parnell Pharmaceuticals Holdings in a research report on Wednesday, August 12th.


Parnell Pharmaceuticals Holdings (NASDAQ:PARN) traded down 1.8844% during trading on Wednesday, hitting $3.6499. The stock had a trading volume of 404 shares. The company has a market capitalization of $52.83 million and a price-to-earnings ratio of 11.1960. Parnell Pharmaceuticals Holdings has a 12-month low of $3.20 and a 12-month high of $6.00. The stock has a 50 day moving average price of $3.88 and a 200 day moving average price of $4.32.

Parnell Pharmaceuticals Holdings (NASDAQ:PARN) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.26) by $0.07. Equities research analysts forecast that Parnell Pharmaceuticals Holdings will post ($0.87) earnings per share for the current year.

Parnell Pharmaceuticals Holdings Ltd. is a veterinary pharmaceutical company. The Company is focused on developing, manufacturing and commercializing health solutions. The principal activities of the Company include manufacture for global sale of animal pharmaceutical product and research and development of pharmaceutical products for global animal health markets. It operates in four segments: Companion Animal, which covers its Osteoarthritis portfolios across both Canine and Equine species; Production Animal-U.S., which covers its Reproductive Hormone portfolio across Production Animal in the United States of America; Production Animal-Rest of World, which covers the its reproductive hormone portfolio in Production Animal across all regions outside of the United States of America and Manufacturing Operations is responsible for the operation its Food and Drug Administration approved sterile manufacturing facility and the manufacture and release of all its pharmaceutical products.


http://www.tickerreport.com/banking-finance/861066/parnell-pharmaceuticals-holdings-upgraded-to-hold-by-zacks-parn/